311 related articles for article (PubMed ID: 25271258)
1. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432.
Lord B; Aluisio L; Shoblock JR; Neff RA; Varlinskaya EI; Ceusters M; Lovenberg TW; Carruthers N; Bonaventure P; Letavic MA; Deak T; Drinkenburg W; Bhattacharya A
J Pharmacol Exp Ther; 2014 Dec; 351(3):628-41. PubMed ID: 25271258
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.
Bhattacharya A; Wang Q; Ao H; Shoblock JR; Lord B; Aluisio L; Fraser I; Nepomuceno D; Neff RA; Welty N; Lovenberg TW; Bonaventure P; Wickenden AD; Letavic MA
Br J Pharmacol; 2013 Oct; 170(3):624-40. PubMed ID: 23889535
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia.
Bhattacharya A; Lord B; Grigoleit JS; He Y; Fraser I; Campbell SN; Taylor N; Aluisio L; O'Connor JC; Papp M; Chrovian C; Carruthers N; Lovenberg TW; Letavic MA
Neuropsychopharmacology; 2018 Dec; 43(13):2586-2596. PubMed ID: 30026598
[TBL] [Abstract][Full Text] [Related]
4. A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334.
Lord B; Ameriks MK; Wang Q; Fourgeaud L; Vliegen M; Verluyten W; Haspeslagh P; Carruthers NI; Lovenberg TW; Bonaventure P; Letavic MA; Bhattacharya A
Eur J Pharmacol; 2015 Oct; 765():551-9. PubMed ID: 26386289
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of
Kolb HC; Barret O; Bhattacharya A; Chen G; Constantinescu C; Huang C; Letavic M; Tamagnan G; Xia CA; Zhang W; Szardenings AK
J Nucl Med; 2019 Aug; 60(8):1154-1159. PubMed ID: 30733317
[TBL] [Abstract][Full Text] [Related]
7. Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy.
Jimenez-Pacheco A; Diaz-Hernandez M; Arribas-Blázquez M; Sanz-Rodriguez A; Olivos-Oré LA; Artalejo AR; Alves M; Letavic M; Miras-Portugal MT; Conroy RM; Delanty N; Farrell MA; O'Brien DF; Bhattacharya A; Engel T; Henshall DC
J Neurosci; 2016 Jun; 36(22):5920-32. PubMed ID: 27251615
[TBL] [Abstract][Full Text] [Related]
8.
Koole M; Schmidt ME; Hijzen A; Ravenstijn P; Vandermeulen C; Van Weehaeghe D; Serdons K; Celen S; Bormans G; Ceusters M; Zhang W; Van Nueten L; Kolb H; de Hoon J; Van Laere K
J Nucl Med; 2019 May; 60(5):683-690. PubMed ID: 30262518
[TBL] [Abstract][Full Text] [Related]
9. P2X7 receptors at adult neural progenitor cells of the mouse subventricular zone.
Messemer N; Kunert C; Grohmann M; Sobottka H; Nieber K; Zimmermann H; Franke H; Nörenberg W; Straub I; Schaefer M; Riedel T; Illes P; Rubini P
Neuropharmacology; 2013 Oct; 73():122-37. PubMed ID: 23727220
[TBL] [Abstract][Full Text] [Related]
10. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor.
Hempel C; Nörenberg W; Sobottka H; Urban N; Nicke A; Fischer W; Schaefer M
Neuropharmacology; 2013 Dec; 75():365-79. PubMed ID: 23954492
[TBL] [Abstract][Full Text] [Related]
11. Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat.
Able SL; Fish RL; Bye H; Booth L; Logan YR; Nathaniel C; Hayter P; Katugampola SD
Br J Pharmacol; 2011 Jan; 162(2):405-14. PubMed ID: 20840537
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139.
Hopper AT; Juhl M; Hornberg J; Badolo L; Kilburn JP; Thougaard A; Smagin G; Song D; Calice L; Menon V; Dale E; Zhang H; Cajina M; Nattini ME; Gandhi A; Grenon M; Jones K; Khayrullina T; Chandrasena G; Thomsen C; Zorn SH; Brodbeck R; Poda SB; Staal R; Möller T
J Med Chem; 2021 Apr; 64(8):4891-4902. PubMed ID: 33822617
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
Recourt K; van der Aart J; Jacobs G; de Kam M; Drevets W; van Nueten L; Kanhai K; Siebenga P; Zuiker R; Ravenstijn P; Timmers M; van Gerven J; de Boer P
J Psychopharmacol; 2020 Sep; 34(9):1030-1042. PubMed ID: 32248747
[TBL] [Abstract][Full Text] [Related]
14. P2X7 receptor antagonist activity of the anti-allergic agent oxatomide.
Yoshida K; Ito M; Matsuoka I
Eur J Pharmacol; 2015 Nov; 767():41-51. PubMed ID: 26463039
[TBL] [Abstract][Full Text] [Related]
15. Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages.
Gicquel T; Victoni T; Fautrel A; Robert S; Gleonnec F; Guezingar M; Couillin I; Catros V; Boichot E; Lagente V
Clin Exp Pharmacol Physiol; 2014 Apr; 41(4):279-86. PubMed ID: 24472059
[TBL] [Abstract][Full Text] [Related]
16. Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1
Ruiz-Ruiz C; García-Magro N; Negredo P; Avendaño C; Bhattacharya A; Ceusters M; García AG
Dis Model Mech; 2020 Oct; 13(10):. PubMed ID: 33174532
[TBL] [Abstract][Full Text] [Related]
17. Translational Model-Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ-54175446, a P2X7 Receptor Antagonist.
Xu Y; Miao X; Ravenstijn P; Hijzen A; Schmidt ME; Nandy P; Zhou H
Clin Transl Sci; 2020 Mar; 13(2):309-317. PubMed ID: 31642608
[TBL] [Abstract][Full Text] [Related]
18. P2X7 receptor antagonism reduces the severity of spontaneous seizures in a chronic model of temporal lobe epilepsy.
Amhaoul H; Ali I; Mola M; Van Eetveldt A; Szewczyk K; Missault S; Bielen K; Kumar-Singh S; Rech J; Lord B; Ceusters M; Bhattacharya A; Dedeurwaerdere S
Neuropharmacology; 2016 Jun; 105():175-185. PubMed ID: 26775823
[TBL] [Abstract][Full Text] [Related]
19. N-Alkyl-Substituted Isatins Enhance P2X7 Receptor-Induced Interleukin-1β Release from Murine Macrophages.
Sluyter R; Vine KL
Mediators Inflamm; 2016; 2016():2097219. PubMed ID: 27524862
[TBL] [Abstract][Full Text] [Related]
20. The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1
Ly D; Dongol A; Cuthbertson P; Guy TV; Geraghty NJ; Sophocleous RA; Sin L; Turner BJ; Watson D; Yerbury JJ; Sluyter R
Purinergic Signal; 2020 Mar; 16(1):109-122. PubMed ID: 32170537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
